Toxicity and Inflammatory Response of Melamine Cyanurate
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Expression of the Alpha, Beta, and Gamma Subunits of the Interleukin-2
Expression of the Alpha, Beta, and Gamma Subunits of the Interleukin-2 Receptor by Human Vascular Smooth Muscle Cells A thesis submitted in partial fulfillment Of the requirements for the degree of Master of Science By Sultan Alhayyani B.S. King Abdulaziz University 2014 Wright State University WRIGHT STATE UNIVERSITY SCHOOL OF GRADUATE STUDIES April 14, 2014 I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY SUPERVISION BY SULTAN ALHAYYANI ENTITLED EXPRESSION OF THE ALPHA, BETA, AND GAMMA SUBUNITS OF THE INTERLEUKIN-2 RECEPTOR BY HUMAN VASCULAR SMOOTH MUSCLE CELLS BE ACCEPTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF Master of Science. Lucile Wrenshall, MD, Ph.D. Thesis Director Committee on Final Examination Lucile Wrenshall, MD, Ph.D. Barbara E. Hull, Ph.D. Professor of Neuroscience, Cell Biology, and Director of Microbiology and Physiology Immunology Program, College of Science and Mathematics Barbara E. Hull, Ph.D. Professor of Biological Sciences Nancy J. Bigley, Ph.D. Professor of Microbiology and Immunology John Miller, Ph.D. Adjunct Assistant Professor Of Neuroscience, Cell Biology, and Physiology Robert E. W. Fyffe, Ph.D. Vice President of Research and Dean of the Graduate School ABSTRACT Alhayyani, Sultan. M.S. Microbiology and Immunology Graduate Program, Wright State University, 2014. Expression of the Alpha, Beta, and Gamma Subunits of the Interleukin-2 Receptor by Human Vascular Smooth Muscle Cells. Interleukin 2 (IL-2) is a member of the cytokine family and contributes to the proliferation, survival, and death of lymphocytes [1]. The interleukin-2 receptor (IL-2) is a tripartite receptor commonly expressed on the surfaces of many lymphoid cells and is composed of three non-covalently associated subunits, alpha (α) (CD25), beta (β) (CD122), and gamma (γ) (CD132) [2]. -
United States Patent (19) 11 Patent Number: 5,766,866 Center Et Al
USOO5766866A United States Patent (19) 11 Patent Number: 5,766,866 Center et al. 45) Date of Patent: Jun. 16, 1998 54 LYMPHOCYTE CHEMOATTRACTANT Center, et al. The Journal of Immunology. 128:2563-2568 FACTOR AND USES THEREOF (1982). 75 Inventors: David M. Center. Wellesley Hills; Cruikshank, et al. The Journal of Immunology, William W. Cruikshank. Westford; 138:3817-3823 (1987). Hardy Kornfeld, Brighton, all of Mass. Cruikshank, et al., The Journal of Immunology, 73) Assignee: Research Corporation Technologies, 146:2928-2934 (1991). Inc., Tucson, Ariz. Cruikshank, et al., EMBL Database. Accession No. M90301 (21) Appl. No.: 580,680 (1992). 22 Filed: Dec. 29, 1995 Cruikshank. et al. The Journal of Immunology, 128:2569-2574 (1982). Related U.S. Application Data Rand, et al., J. Exp. Med., 173:1521-1528 (1991). 60 Division of Ser. No. 480,156, Jun. 7, 1995, which is a continuation-in-part of Ser. No. 354,961, Dec. 13, 1994, Harlow (1988) Antibodies, a laboratory manual. Cold Spring which is a continuation of Ser. No. 68,949, May 21, 1993, Harbor Laboratory, 285, 287. abandoned. Waldman (1991) Science. vol. 252, 1657-1662. (51) Int. Cl. ....................... G01N 33/53; CO7K 1700; CO7K 16/00: A61K 45/05 Hams et al. (1993) TIBTECH Feb. 1993 vol. 111, 42-44. 52 U.S. Cl. ......................... 424/7.24; 435/7.1; 435/7.92: 435/975; 530/350:530/351; 530/387.1: Center, et al. (Feb. 1995) "The Lymphocyte Chemoattractant 530/388.23: 530/389.2: 424/85.1: 424/130.1 Factor”. J. Lab. Clin. Med. 125(2):167-172. -
Interleukin 2 Medical Intensive Care Unit (4MICU)
Interleukin 2 Medical Intensive Care Unit (4MICU) Ronald Reagan UCLA Medical Center 757 Westwood Plaza Los Angeles, CA 90095 Main Phone: (310) 267-7441 Fax: (310) 267-3785 About Our Unit The Medical Intensive Care Unit (MICU) cares Quick for critically ill patients in an intensive care Reference Guide environment, with nursing staff specially trained in the administration of Interleukin 2 therapy. Unit Director / Manager Mark Flitcraft, RN, MSN One registered nurse (RN) is assigned to take (310) 267-9529 care of a maximum of two patients. Our Medical Clinical Nurse Specialist Intensive Care Unit patient rooms are designed Yuhan Kao, RN, MSN, CNS (310) 267-7465 to allow nurses constant visual contact with their patients. As a safety precaution, the Medical Assistant Manager Sherry Xu, RN, BA, CCRN Intensive Care Unit is a closed unit and requires (310) 267-7485 permission to enter by intercom. Clinical Case Manager Each private-patient-care room contains the Connie Lefevre (310) 267-9740 most advanced intensive-care equipment available, including cardiac-monitoring and Clinical Social Worker Codie Lieto emergency-response equipment. The curtains in (310) 267-9741 the room will usually be drawn to keep your room Charge Nurse On-Duty more private. (310) 267-7480 or (310) 267-7482 A brief tour is available on weekdays for patients and visitors interested in walking through the unit Patient Affairs (310) 267-9113 and meeting the staff before arrival. To arrange for a tour, please call the nurse manager at Respiratory Supervisor (310) 267-9529. Orna Molayeme, MA, RCP, RRT, NPS (310) 267-8921 UCLAHEALTH.ORG 1-800-UCLA-MD1 (1-800-825-2631) About Our Unit During Your Stay Quick The Medical Team Reference Guide During each shift, you will be assigned a registered nurse (RN) and a clinical care partner (CCP). -
The Comparison of Interleukin-17 and Interleukin-10 with Systemic Lupus Erythematosus Disease Activity
Scientific Foundation SPIROSKI, Skopje, Republic of Macedonia Open Access Macedonian Journal of Medical Sciences. 2020 Aug 25; 8(B):793-797. https://doi.org/10.3889/oamjms.2020.4782 eISSN: 1857-9655 Category: B - Clinical Sciences Section: Rheumatology The Comparison of Interleukin-17 and Interleukin-10 with Systemic Lupus Erythematosus Disease Activity Dwitya Elvira1, Iris Rengganis1*, Rudy Hidayat2, Hamzah Shatri3 1Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine University of Indonesia- Cipto Mangunkusumo Hospital, Jakarta, Indonesia; 2Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine University of Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia; 3Division of Psychosomatic and Palliative Medicine, Department of Internal Medicine, Faculty of Medicine University of Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia Abstract Edited by: Slavica Hristomanova-Mitkovska AIM: This study was conducted to compare means of interleukin-17 (IL-17) (Th17 cytokines) and interleukin-10 Citation: Elvira D, Rengganis I, Hidayat R, Shatri H. The Comparison of Interleukin-17 and Interleukin-10 with (IL-10) (T-regulatory cytokines) as pro-inflammatory and anti-inflammatory cytokine with disease activity of systemic Systemic Lupus Erythematosus Disease Activity. Open lupus erythematosus (SLE) and to investigate correlation between IL-17 cytokine serums with IL-10 in SLE patients. Access Maced J Med Sci. 2020 Aug 25; 8(B):793-797. https:// doi.org/10.3889/oamjms.2020.4782 METHODS: This study recruited total of 68 SLE patients which included 34 active and 34 inactive patients based Keywords: Interleukin-17; Interleukin-10; Systemic lupus erythematosus; Disease activity on MEX-SLEDAI as disease activity tool measurement and subjects were selected using consecutive sampling *Correspondence: Iris Rengganis, Division of Allergy and method. -
IL-1Β Induces the Rapid Secretion of the Antimicrobial Protein IL-26 From
Published June 24, 2019, doi:10.4049/jimmunol.1900318 The Journal of Immunology IL-1b Induces the Rapid Secretion of the Antimicrobial Protein IL-26 from Th17 Cells David I. Weiss,*,† Feiyang Ma,†,‡ Alexander A. Merleev,x Emanual Maverakis,x Michel Gilliet,{ Samuel J. Balin,* Bryan D. Bryson,‖ Maria Teresa Ochoa,# Matteo Pellegrini,*,‡ Barry R. Bloom,** and Robert L. Modlin*,†† Th17 cells play a critical role in the adaptive immune response against extracellular bacteria, and the possible mechanisms by which they can protect against infection are of particular interest. In this study, we describe, to our knowledge, a novel IL-1b dependent pathway for secretion of the antimicrobial peptide IL-26 from human Th17 cells that is independent of and more rapid than classical TCR activation. We find that IL-26 is secreted 3 hours after treating PBMCs with Mycobacterium leprae as compared with 48 hours for IFN-g and IL-17A. IL-1b was required for microbial ligand induction of IL-26 and was sufficient to stimulate IL-26 release from Th17 cells. Only IL-1RI+ Th17 cells responded to IL-1b, inducing an NF-kB–regulated transcriptome. Finally, supernatants from IL-1b–treated memory T cells killed Escherichia coli in an IL-26–dependent manner. These results identify a mechanism by which human IL-1RI+ “antimicrobial Th17 cells” can be rapidly activated by IL-1b as part of the innate immune response to produce IL-26 to kill extracellular bacteria. The Journal of Immunology, 2019, 203: 000–000. cells are crucial for effective host defense against a wide and neutrophils. -
Evolutionary Divergence and Functions of the Human Interleukin (IL) Gene Family Chad Brocker,1 David Thompson,2 Akiko Matsumoto,1 Daniel W
UPDATE ON GENE COMPLETIONS AND ANNOTATIONS Evolutionary divergence and functions of the human interleukin (IL) gene family Chad Brocker,1 David Thompson,2 Akiko Matsumoto,1 Daniel W. Nebert3* and Vasilis Vasiliou1 1Molecular Toxicology and Environmental Health Sciences Program, Department of Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO 80045, USA 2Department of Clinical Pharmacy, University of Colorado Denver, Aurora, CO 80045, USA 3Department of Environmental Health and Center for Environmental Genetics (CEG), University of Cincinnati Medical Center, Cincinnati, OH 45267–0056, USA *Correspondence to: Tel: þ1 513 821 4664; Fax: þ1 513 558 0925; E-mail: [email protected]; [email protected] Date received (in revised form): 22nd September 2010 Abstract Cytokines play a very important role in nearly all aspects of inflammation and immunity. The term ‘interleukin’ (IL) has been used to describe a group of cytokines with complex immunomodulatory functions — including cell proliferation, maturation, migration and adhesion. These cytokines also play an important role in immune cell differentiation and activation. Determining the exact function of a particular cytokine is complicated by the influence of the producing cell type, the responding cell type and the phase of the immune response. ILs can also have pro- and anti-inflammatory effects, further complicating their characterisation. These molecules are under constant pressure to evolve due to continual competition between the host’s immune system and infecting organisms; as such, ILs have undergone significant evolution. This has resulted in little amino acid conservation between orthologous proteins, which further complicates the gene family organisation. Within the literature there are a number of overlapping nomenclature and classification systems derived from biological function, receptor-binding properties and originating cell type. -
IL-1/IL-3 Gene Therapy of Non-Small Cell Lung Cancer (NSCLC) in Rats Using ‘Cracked’ Adenoproducer Cells
Gene Therapy (1998) 5, 778–788 1998 Stockton Press All rights reserved 0969-7128/98 $12.00 http://www.stockton-press.co.uk/gt IL-1/IL-3 gene therapy of non-small cell lung cancer (NSCLC) in rats using ‘cracked’ adenoproducer cells MC Esandi1,2, GD van Someren1, A Bout3, AH Mulder4, DW van Bekkum3, D Valerio1,3 and JL Noteboom1,5 1Section Gene Therapy, Department of Molecular Cell Biology, Leiden University; 3IntroGene BV, Leiden; and 4Pathologisch Laboratorium, Dordrecht, The Netherlands Cytokine gene therapy was studied in established L42 tumour responses. These were due to local release of cyto- tumours in syngeneic rats. L42 is a transplantable non- kines, not to systemic effects. Growth retardation also immunogenic non-small cell lung cancer (NSCLC). Genes occurred in contralateral tumours which were not injected. coding for human interleukin-1␣ and for rat interleukin-3 When rats carrying established tumours were vaccinated were transferred by injecting producer cells of recombinant with lysates of tumours collected during treatment with adenovirus vectors into the tumour in attempts to achieve ‘cracked’ producer cells, significant tumour growth retar- high concentrations of the cytokines inside the tumor with- dation was obtained. We speculate that both cytokines, if out systemic toxicity. Limited tumour growth delay was produced at sufficiently high concentrations in tumours, obtained with viable producer cells. For logistic reasons induce inflammation which in turn initiates an immune stocks of pooled frozen producer cells allowed intensive response against tumours growing at a distant site. These treatment of groups of tumour bearing rats. The cells were findings seem to justify further exploration of IL-1 and IL-3 lysed by thawing before administration. -
Inducing Cytokines − and IL-10 Inhibits IL-17 Response by Eliciting
The Journal of Immunology The TLR7 Ligand 9-Benzyl-2-Butoxy-8-Hydroxy Adenine Inhibits IL-17 Response by Eliciting IL-10 and IL-10–Inducing Cytokines Alessandra Vultaggio,*,1 Francesca Nencini,†,‡,1 Sara Pratesi,†,‡ Laura Maggi,†,‡ Antonio Guarna,x Francesco Annunziato,†,‡ Sergio Romagnani,†,‡ Paola Parronchi,†,‡ and Enrico Maggi†,‡ This study evaluates the ability of a novel TLR7 ligand (9-benzyl-2-butoxy-8-hydroxy adenine, called SA-2) to affect IL-17 response. The SA-2 activity on the expression of IL-17A and IL-17–related molecules was evaluated in acute and chronic models of asthma as well as in in vivo and in vitro a-galactosyl ceramide (a-GalCer)-driven systems. SA-2 prepriming reduced neutrophils in bronchoalveolar lavage fluid and decreased methacoline-induced airway hyperresponsiveness in murine asthma models. These results were associated with the reduction of IL-17A (and type 2 cytokines) as well as of molecules favoring Th17 (and Th2) development in lung tissue. The IL-17A production in response to a-GalCer by spleen mononuclear cells was inhibited in vitro by the presence of SA-2. Reduced IL-17A (as well as IFN-g and IL-13) serum levels in mice treated with a-GalCer plus SA-2 were also observed. The in vitro results indicated that IL-10 produced by B cells and IL-10–promoting molecules such as IFN-a and IL- 27 by dendritic cells are the major player for SA-2–driven IL-17A (and also IFN-g and IL-13) inhibition. The in vivo experiments with anti-cytokine receptor Abs provided evidence of an early IL-17A inhibition essentially due to IL-10 produced by resident peritoneal cells and of a delayed IL-17A inhibition sustained by IFN-a and IL-27, which in turn drive effector T cells to IL-10 production. -
Rapid and Rigorous IL-17A Production by a Distinct
Rapid and Rigorous IL-17A Production by a Distinct Subpopulation of Effector Memory T Lymphocytes Constitutes a Novel Mechanism of Toxic Shock Syndrome Immunopathology This information is current as of September 28, 2021. Peter A. Szabo, Ankur Goswami, Delfina M. Mazzuca, Kyoungok Kim, David B. O'Gorman, David A. Hess, Ian D. Welch, Howard A. Young, Bhagirath Singh, John K. McCormick and S. M. Mansour Haeryfar J Immunol published online 20 February 2017 Downloaded from http://www.jimmunol.org/content/early/2017/02/18/jimmun ol.1601366 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2017/02/18/jimmunol.160136 Material 6.DCSupplemental Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 28, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2017 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published February 20, 2017, doi:10.4049/jimmunol.1601366 The Journal of Immunology Rapid and Rigorous IL-17A Production by a Distinct Subpopulation of Effector Memory T Lymphocytes Constitutes a Novel Mechanism of Toxic Shock Syndrome Immunopathology Peter A. -
Human Interleukin 2 Analogues That Preferentially Bind the Intermediate-Affinity Interleukin 2 Receptor Lead to Reduced Secondar
[CANCER RESEARCH 53. 2597-2«)2. June I. 1993] Human Interleukin 2 Analogues That Preferentially Bind the Intermediate-Affinity Interleukin 2 Receptor Lead to Reduced Secondary Cytokine Secretion: Implications for the Use of These Interleukin 2 Analogues in Cancer Immunotherapy ' Keith M. Heaton,2 Grace Ju, and Elizabeth A. Grimm neiHirnneiiis ctf Tumor rìitìlogydittiGeneral Surgen; the University of Te\as M. D. Anderson Ccincer Center. Hmtuon. Te\(ts 77030 fK. M. H.. E. A. G.J. anil the Department of Inflamtiiiition/Aittotinintine Diseii\e.\. HvffnHinn-lMRfciie. Inc.. M/f/cv. New Jersey 07110 ¡G.J.¡ ABSTRACT Many of the signs and symptoms of IL-2-induced toxicity are thought to be caused by the actions of cytokines such as IL-lß. Cancer patients undergoing interleukin (IL)-2-based immunotherapy TNF-a, TNF-ß.and IFN-y released by IL-2-activated PBMC (9-14). frequently experience dose-limiting side effects believed to be caused by the actions of such cytokines as II.-I/Î,tumor necrosis factor (TNF)-a and If secretion of these secondary cytokines could be reduced, patients -ß,and interferon-y (IFN-y). Human peripheral blood mononuclear cells receiving IL-2 immunotherapy might be able to tolerate higher and (PBMC) or monocyte-dcpleted peripheral blood lymphocytes »erestim more effective doses of IL-2. ulated for up to 7 days by either of 2 IL-2 analogues (R38A or F42K) that R38A and F42K. 2 human IL-2 analogues that have altered IL-2Ra bind to the intermediate-affinity II.-2/jy receptor but have reduced abil binding domains, differ from human rIL-2 by a single amino acid ities to bind the high-affinity II -2 receptor. -
The Impact of a New Interleukin-2-Based Immunotherapy Candidate on Urothelial Cells to Support Use for Intravesical Drug Delivery
life Article The Impact of a New Interleukin-2-Based Immunotherapy Candidate on Urothelial Cells to Support Use for Intravesical Drug Delivery Lisa Schmitz 1,*, Belinda Berdien 2, Edith Huland 2, Petra Dase 1, Karin Beutel 1, Margit Fisch 1 and Oliver Engel 1 1 Department of Urology, University Medical Center Hamburg-Eppendorf (UKE), 20251 Hamburg, Germany; [email protected] (P.D.); [email protected] (K.B.); [email protected] (M.F.); [email protected] (O.E.) 2 Immunservice GmbH, 20251 Hamburg, Germany; [email protected] (B.B.); [email protected] (E.H.) * Correspondence: [email protected] Received: 18 August 2020; Accepted: 2 October 2020; Published: 5 October 2020 Abstract: (1) Background: The intravesical instillation of interleukin-2 (IL-2) has been shown to be very well tolerated and promising in patients with bladder malignancies. This study aims to confirm the use of a new IL-2 containing immunotherapy candidate as safe for intravesical application. IL-2, produced in mammalian cells, is glycosylated, because of its unique solubility and stability optimized for intravesical use. (2) Materials and Methods: Urothelial cells and fibroblasts were generated out of porcine bladder and cultured until they reached second passage. Afterwards, they were cultivated in renal epithelial medium (REM) and Dulbecco’s modified Eagles medium (DMEM) with the IL-2 candidate (IMS-Research) and three more types of human interleukin-2 immunotherapy products (IMS-Pure, Natural IL-2, Aldesleukin) in four different concentrations (100, 250, 500, 1000 IU/mL). Cell proliferation was analyzed by water soluble tetrazolium (WST) proliferation assay after 0, 3, and 6 days for single cell culture and co-culture. -
330, 329, 357 Acquired/Secondary
j689 Index a acute/chronic pulmonary Acanthamoeba castellanii 152 histoplasmosis 567 acid-fast staining 327 ACV trafficking 248 acquired immune deficiency syndrome adaptive immune system 217 (AIDS) 330, 329, 357 – antigen processing 225–230 acquired/secondary mutualistic – B cells, antibodies and immunity endosymbionts 553–554 224–225 þ actin-associated proteins 131 – CD4 TH1 217–220 actin-based motility system 440, 435 – cells of 217–225 þ – process 435 – cytotoxic CD8 T lymphocytes 221–222 actin-binding proteins (ABPs) 126, 127 – natural killer T lymphocytes 222–223 – coronin 337 – regulatory T cells 223–224 – filamin 130 – T cell receptors 225 – SipA 379 – ab T cells 217 actin cytoskeleton 126, 135 – gd TCRT lymphocytes 222 – background 126 – TH2 lymphocytes 217–220 – – – disruption 135 TH17 lymphocytes 220 221 actin-dependent process 132 adaptive virulence mechanisms 27 – phagocytosis 289 adenylate kinase 133 actin depolymerization factor (ADF) 127 ADP-actin 129 actin filament 129 ADP-Pi-bound monomers 126 actin interactions 128 ADP-ribosylation factor 1(Arf1) 71 – binding 128 ADP transporter 133 – nucleation 128 Aerobacter aerogenes 21 actin monomers 127 Afipia felis 237, 239, 240, 242, 248, see also cat actin nucleation assay, schematic scratch disease presentation 130 – containing phagosome 240, 241, 242, 249, actin polymerization process 116, 129, 243, 251 247 – immunology 251–252 – inhibitor 399 – intracellular bacterium 239 – machinery, lipophosphoglycan (LPG)- – intracellular fate determination 246–248 mediated retention 590 – low-efficiency uptake pathway 242–243 actin-recruiting protein 277 – macrophages 246 actin-remodeling proteins 118 – uptake/intracellular compartmentation actin-rich bacteria-containing membrane, model 240, 248 formation 402 Agrobacterium tumefaciens 311, 575 actin system 126 – Cre recombinase reporter assay 311 Intracellular Niches of Microbes.